Boston Scientific price target raised to $83 from $81 at Canaccord

Canaccord raised the firm’s price target on Boston Scientific to $83 from $81 and keeps a Buy rating on the shares. The firm believes the company’s ability to drive top-line growth, while still staying focused on improving leverage can continue, and could prove to be a historic run for this strategic med-tech.